Published on 24 Feb 2022 on Zacks via Yahoo Finance
Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus
Arena Pharmaceuticals, Inc. ARNA incurred a loss of $2.54 per share for fourth-quarter 2021, wider than the Zacks Consensus Estimate of a loss of $2.41 and the year-ago loss of $2.10.
Arena Pharmaceuticals recorded $0.05 million of revenues for the reported quarter. The Zacks Consensus Estimate for revenues was nil. ARNA recorded revenues of $0.04 million in the year-ago quarter.
Shares of ARNA have risen 17.3% in the trailing 12 months against the industry’s 40.7% decrease.